Clinical Trial Update: Phase 1/2a Study of VK-2019 in Patients With Epstein-Barr Virus (EBV)-Positive Nasopharyngeal Carcinoma (NPC) [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2a study of VK-2019 in EBV-positive nasopharyngeal carcinoma was terminated; results posted in 2023.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Nasopharyngeal Carcinoma

Drugs mentioned

• VK 2019 (VK-2019 EBNA1 inhibitor)

Snippet

Sponsor: Cullinan Therapeutics Inc. | Conditions: Nasopharyngeal Carcinoma, Nasopharyngeal Cancer | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2023-08-15